Do More With Reuters
Partner Services

Astra seeks U.S. okay for Seroquel XR in anxiety

Thu May 8, 2008 3:46pm IST
 
Email | Print | | Single Page
[-] Text [+]

LONDON, May 8 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile, Research) said on Thursday it had applied to U.S. regulators to sell its schizophrenia drug Seroquel XR as a treatment for anxiety.

If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalised anxiety disorder.

Seroquel XR -- a follow-on extended release version of AstraZeneca's older $4 billion-a-year seller Seroquel -- was approved in the United States for schizophrenia in 2007. AstraZeneca is also seeking clearance to sell the new drug for bipolar disorder. (Reporting by Ben Hirschler)

Britain's Prime Minister Gordon Brown speaks, as finance minister Alistair Darling listens at the G20 Finance Ministers meeting in St. Andrews, Scotland. REUTERS/POOL New
UK joins G20 push for world levy on banks

Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change.  Full Article | Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

column

Nipun Mehta
Nipun Mehta, SG Private Banking
India - planning the road to recovery

There needs to be an acceptable balance created between education & healthcare and infrastructure spend.  Full Article 

SHOWCASE

Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Out of Woods?
Out of the Woods?

Analysis - CIT's bankruptcy exit fraught with uncertainty  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article